文献速递妇科产科

晚期卵巢癌减灭术围手术期不良事件风险计算器的独立验证

Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
PubMed 文献 · Gynecol Oncol · 2020-12-04

本研究在高容量手术中心独立验证已发表的预测上皮性卵巢癌减灭术后不良围手术期结局的风险计算器。纳入2015年7月至2019年5月700例患者,联合并发症率为11.7%,列线图区分度良好(c指数0.715,95%CI 0.66-0.768),与原始发表相当。该工具能较好预测严重术后并发症低概率,但需增强版识别高风险患者。

要点

  • 联合并发症率为11.7%,再入院率9.9%,再手术率2.7%。
  • 脓毒症最常见(4.4%),其次感染性休克(1.4%),无30天死亡。
  • 列线图c指数0.715(95%CI 0.66-0.768),验证表现良好。

核心结论

  • 该列线图在高容量手术中心独立验证中表现良好,能预测严重术后并发症低概率。
  • 需增强版列线图以识别严重并发症高风险患者。

研究设计与样本

  • 利用机构前瞻性卵巢癌数据库,纳入2015年7月至2019年5月接受减灭术的上皮性卵巢癌患者作为验证队列。
  • 纳入标准为列线图所有变量信息完整且具备30天随访,共700例符合。
  • 收集变量包括ASA分级、术前白蛋白、出血性疾病史、术前影像腹水、择期或急诊手术、年龄和手术评分。

主要发现

  • 联合并发症率(Clavien-Dindo IV级特定情况与30天死亡组合)为11.7%。
  • 9.9%患者再入院,2.7%需再手术。
  • 脓毒症为最常见主要终点并发症(4.4%),其次感染性休克(1.4%)。
  • 队列中无30天死亡。
  • 列线图c指数为0.715(95%CI 0.66-0.768),与发表版相当。

关键数值与推荐

  • 主要终点为Clavien-Dindo IV级特定情况(术后脓毒症、感染性休克、心脏骤停、心肌梗死、肺栓塞、通气>48小时或非计划插管)与30天死亡组合。

临床怎么用

  • 该列线图可用于预测上皮性卵巢癌减灭术后严重并发症低概率,辅助围手术期风险评估。
  • 对预测低概率患者可支持手术决策,但高风险患者识别仍需增强工具。

局限性

  • 单中心高容量手术中心验证,外推性需多中心确认。
  • 仅纳入变量完整且有30天随访患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To independently validate a published risk-calculator for adverse perioperative outcomes in patients with epithelial ovarian cancer undergoing debulking surgery at a high-volume surgical center. METHODS: Using our institution's curated prospective ovarian cancer database, we identified patients with epithelial ovarian cancer who underwent a debulking procedure from 7/2015 to 5/2019, to be used as the validation cohort. Variables used in the published nomogram were collected. These included American Society of Anesthesiology classification, preoperative albumin, history of bleeding disorder, presence of ascites on preoperative imaging, designation of elective or emergent surgery, age of the patient, and a procedure score. Patients were included if they had information available for all the variables used in the nomogram, and 30-day follow-up within our institution. The primary outcome was Clavien-Dindo Class IV with specific conditions (postoperative sepsis, septic shock, cardiac arrest, myocardial infarction, pulmonary embolism, ventilation >48 h, or unplanned intubation) and 30-day mortality. The combination of these endpoints is called the combined complication rate. RESULTS: A total of 700 patients who underwent debulking surgery for epithelial ovarian cancer during the timeframe met inclusion criteria. The combined complication rate was 11.7%; 9.9% of patients were readmitted; 2.7% required reoperation. Sepsis was the most common primary endpoint complication (4.4%), followed by septic shock (1.4%). There was no 30-day mortality in our cohort. The nomogram performed well, with a c index of 0.715 (95% CI 0.66-0.768), which was comparable to the published nomogram. CONCLUSIONS: We independently validated a complication nomogram at a high-volume surgical center. This nomogram performs well at predicting a lower likelihood of serious postoperative complications. An enhanced nomogram would help identify patients at higher risk for serious complications.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Straubhar AM, Wolf JL, Zhou MQC, et al. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. Gynecol Oncol. 2020. PMID: 33272645. doi:10.1016/j.ygyno.2020.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。